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SUMMARY:  Blood glucose levels in the high normal range or even moderate hyperglycemia is the expected profile in septic postoperative patients
receiving high-calorie enteral alimentation. The addition of growth hormone as an anabolic agent should additionally reinforce this tendency. In a cancer
patient undergoing partial gastrectomy with lymphadenectomy and suffering from postoperative subphrenic abscess and prolonged sepsis, tube feeding
(38.3 kcal/kg/day) and growth hormone (0.17 IU/kg/day) were simultaneously administered for 25 days. Blood glucose levels were in the lower limits of
the normal range before growth hormone introduction, and continued with a similar tendency during most of the therapeutic period. Two additional com-
plications, namely heart arrest and peripheral edema, were documented during the same period. It is concluded that sepsis was the most likely mecha-
nism for low glucose values, and that high-calorie enteral diet and growth hormone supplementation did not prevent that result. It is uncertain whether
heart arrest was due to the drug, but its association with peripheral edema is well documented in clinical series.
DESCRIPTORS:  Growth Hormone. Enteral Nutrition. Hypoglycemia. Sepsis. Peripheral Edema.
Malnourished cancer patients in the
perioperative period are at high risk for
septic complications3. Nutritional sup-
port, preferably via the enteral route12,
is an accepted modality for accelerat-
ing recovery and inhibiting infectious
complications in this and other critical
situations, and an enhanced result
might be produced by supplementation
with recombinant human growth hor-
mone (GH)22. It is true that in cancer
populations, some studies with GH
failed to demonstrate appreciable ben-
efits15. However, in our own experi-
ence8, as well as in that of others19,
encouraging responses without signifi-
cant side effects have been observed
even in these circumstances.
The present report deals with the
unusual findings of blood glucose
concentrations in an elderly, malnour-
ished, surgical, and septic cancer
patient managed with high-calorie
enteral feeding and adjunctive GH
administration.
CASE REPORT
A 67-year-old male was admitted
with the diagnosis of gastric cancer of
the antrum. Curative subtotal gastrec-
tomy was performed, but a left sub-
phrenic abscess that did not yield to
conservative measures appeared in the
late postoperative period. After 33
days, another laparotomy was indicat-
ed, and the abscess was debrided and
drained. The patient progressed with a
septic course, malnutrition, dependent
edema, pleural effusions, and respira-
tory failure. Mechanical ventilation
was required for a total of 39 days,
and hemodynamic instability
demanding vasoactive drugs occurred
during seven days. 
Throughout the second postopera-
tive hospitalization, cultures from the
wound site and various drains and
catheters revealed Escherichia coli,
Pseudomonas aeruginosa, Entero-
bacter cloacae, Enterococcus faecalis
and Staphyloccocus aureus, which
were treated according to antibiotic
sensitivity tests. White blood cell
counts were permanently elevated
during the hospital stay at levels of
10,400 – 39,000 cells/mm3 .
Nutritional findings at admission:
Height 1.68 m, weight 47.0 kg, body
mass index 16.7 kg/m2, serum albu-
min 30 g/L, hemoglobin concentra-
tion 12.3 g/100 mL.
Dietetic management:  Immedia-
tely after the reoperation, severe ileus
contraindicated use of the gastroin-
testinal tract. Parenteral alimentation
was thus introduced, in the proportion
of 1800 kcal/day (38.3 kcal/kg/day).
By the ninth postoperative day, tube
feeding was phased in, aiming at the
same energy intake and employing a
polymeric commercial diet.
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Anthropometric and biochemical
variables fluctuated during the hospi-
talization period, but without a clear
trend (Table 1). The only exception
was during intermittent episodes of
dependent edema, as well as pleural
effusion, during which body weight
increased and serum albumin dimin-
ished to as little as 23 g/L, requiring
the utilization of albumin replace-
ment, diuretics, and pleural catheter
drainage. Sepsis was a feature of the
entire hospital stay, and so was per-
sistent muscle weakness, preventing
early discontinuation of artificial ven-
tilation (Table 1).
Growth hormone program: On the
16th day after subphrenic abscess
operation, GH therapy was introduced
as an adjunct to the enteral diet, to
stimulate protein anabolism22,
increase muscle strength to enable the
patient to recover vigorous thorax
expansion6, and  enhance the immune
response11. The clinical status of the
patient was not considered incompati-
ble with such medication, since he
didn’t suffer from systemic or
intracranial hypertension, was not dia-
betic, displayed no extrarespiratory
organ failures, and had no clinical evi-
dence of active cancer at that moment.
Given the fact that in subjects
undergoing long-term ventilatory sup-
port, average duration of GH therapy
is in the range of 5–6 weeks6, a pre-
liminary plan of a 4-week supplemen-
tation was defined at 8 IU/day (0.17
IU/kg/day). Actual duration of the
program was 25 days. Nutritional
findings remained stable during this
period. Septic manifestations did not
disappear. However, muscle strength
increased, and the patient was suc-
cessfully weaned from the ventilator
by the end of this time.
Several unexpected episodes
occurred simultaneously with GH use.
The most serious was a heart arrest of
undetermined cause, which occurred
on the seventh day of prescription of
the drug and which was successfully
reversed. The patient developed super-
ficial coma and muscle deficits in the
limbs, but fully recovered in the ensu-
ing two weeks.
Peripheral edema of hands and feet
was the second noteworthy event.
Previously mentioned disturbances
with dependent edema and pleural
effusion did not recur during GH ther-
apy, but by the third week of treatment,
fluid accumulation in the distal part of
the extremities was evident. Shortly
thereafter, the hormone was discontin-
ued, but the patient continued to dis-
play the uncommon feature of large
hands giving the impression of boxing
gloves, as well as comparably swollen
feet, which contrasted with the other-
wise thin and malnourished limbs. The
edema was soft, painless, and easily
depressed, and it disappeared within
approximately three weeks.
During the postoperative course of
the patient, blood glucose levels main-
tained a strange pattern that started
before the introduction of GH and
continued thereafter, requiring con-
stant monitoring and occasional thera-
peutic intervention. Despite the fact
that there were two predisposing con-
ditions for hyperglycemia, namely
septic catabolism and hypercaloric
diet, to which the introduction of GH
further contributed, and despite the
elderly condition of the patient,
glycemic measurements close to the
lowest limit of normal occurred on
various occasions. True hypoglycemia
(below 3.5 mmol/L) was clinically
suspected but never confirmed,
although the complication may have
been masked by frequent administra-
tions of intravenous hypertonic glu-
cose, started prophylactically whenev-
er glucose levels below 4.5 mmol/L
were found.
As a matter of fact, modest hyper-
glycemia did occur as well during a 3-
day period shortly after the heart
arrest, as well as on a few other occa-
sions. Still, the majority of the labora-
tory tests indicated normal or low-
normal readings (Table 2).
DISCUSSION
Depressed blood glucose determi-
nations should not be surprising dur-
ing advanced malnutrition, but sur-
gery and sepsis classically modify this
perspective, due to hormone and
cytokine imbalance. The addition of
GH-therapy is deemed nutritionally
advantageous within this critical set-
ting, but could further damage glu-
cose regulation4,16,17.
Hyperglycemia is definitely con-
sidered a potentially limiting factor
for prescribing GH to elderly or dia-
betic populations1.
Rare pulmonary, pancreatic, or
neuroendocrine cancers manufacture
hormones or peptides with glucose-
lowering properties, but such a find-
ing is extremely unusual for gastric
adenocarcinoma5. Moreover, this
patient maintained normal preopera-
tive glucose concentrations, under-
went radical extirpation of his disease,
and had no evidence of tumor recur-
rence by the time glucose fluctuations
were recognized.
Extensive clinical experience with
GH in adults has never revealed hypo-
glycemia1-3,5, and even direct adminis-
tration of human recombinant IGF-1
to critically ill patients failed to elicit
such an abnormality20. It should be
noted that glucose decreases were
diagnosed before the introduction of
the hormone in the present case.
It would seem a paradox to incrim-
inate sepsis itself for the biochemical
aberration, but severe hypoglycemia
and even hypoglycemic seizures may
on occasion be triggered by bacterial
and parasitic processes7,10,18. Why a
condition so intimately associated with
glucose intolerance should be a possi-
ble cause for the opposite effect is still
incompletely understood. Impaired
gluconeogenesis has been suspected in
this context18, but interleukin-6 could
also be involved with this phenome-
non10. In rats, circulating endotoxin
induces hypoglycemia, among other
effects, and GH may enhance some of
the metabolic responses16.
In the current study, cytokine or
endotoxin measurements were not
available, and gluconeogenesis studies
were not performed. Nevertheless
septic metabolic changes could be the
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predominant explanation for the find-
ings. Hypoglycemia was certainly
demonstrated days ahead of GH use,
in a phase of very severe disease.
Nevertheless, it is interesting to notice
that the anabolic agent did not prevent
its continuation, and perhaps even
contributed toward its maintenance
for some time (Table 2).
As mentioned before, the eventful
course of GH-supplementation in this
experience included two other surpris-
es. Heart arrest is not currently
accepted as a GH-dependent compli-
cation1,2,5,22, and many other circum-
stances could have been responsible
for this accident. Severe electrolyte
imbalance, hypoxia, or heart arrhyth-
mia were ruled out in this mishap, but
the subject was nevertheless a frail
malnourished elderly man with septic
complications and undergoing artifi-
cial ventilation. In our preliminary
results with this agent, no cardiac
abnormalities were detected8, and it is
believed that GH may be beneficial to
heart function in long-term pro-
grams13. Therefore, it is not certain
that GH played a role in this problem.
As regards peripheral edema, it
has been associated with GH adminis-
tration for a long time1,2, but we were
still surprised by its relatively rapid
onset and anatomical severity. Yet this
was a relatively benign complication
with moderate functional impairment,
which was mostly a cosmetic incon-
venience and did not require any spe-
cific treatment. As already indicated,
it was essentially reabsorbed by the
third week.
Perhaps the overarching question
in the entire episode reported here is
the indication and tolerance of GH
pharmacotherapy during critical ill-
ness. There is sufficient evidence in
the literature that sepsis and organ
failures do not preclude a positive
result from such supplementa-
tion4,6,11,16,17,22. In the current case,
recovery of food ingestion and sponta-
neous breathing clearly coincided
with GH administration. At the same
time, it is suspected that elevated mor-
bidity and mortality may also be a
consequence in critical patients, in
some yet insufficiently defined set-
tings21. Whether this depends on the
ability of GH to potentiate the inflam-
matory response to circulating endo-
toxin9, or to interfere with other
endogenous mediators, is presently
unknown and clearly requires further
investigation. 
In conclusion, this was a case of
growth hormone supplementation in a
critically ill, septic postoperative
patient that was followed by a
depressed glycemic pattern, plus two
additional complications, namely heart
arrest, and peripheral edema. A strong
association with the drug can only be
made regarding peripheral edema, but
it may be speculated that the context of
high GH concentrations in a seriously
ill subject could have had deleterious
impact on the other reactions as well.
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Variable / Date  Pre-    GH started Heart arrest GH discontinue 
operative 17th P.O. 23rd P.O 42nd P.O.
Serum albumin (g/L) 30 28 27 34
Hemoglobin (g/dL) 12.3 1.0 10.9 13.0
White blood cells (/mm3 ) 7.9 10.4 39.0 18.4
Obs.: P.O.: Post-operative day
Table 1 - General laboratory  determinations
Day 8AM 2PM 8PM 2AM
13th PO 6.7 4.5 5.5 7.5
14th  “                     3.9 6.4 8.1
15th  “                     5.5 6.4 6.2 7.1
16th  “                     7.0 7.8 6.3 6.3
17th  “  GH started 5.0 7.6 7.6 7.6
18th  “                     5.1 6.0 6.9
19th  “                     6.4 7.8 5.5 6.3
20th  “                    11.9 7.5 8.3
21st  “                     8.8 6.4 9.5 7.6
22nd  “                    9.1 12.5 0.1
23rd “Heart arrest 11.9 7.1 4.8 5.9
24th  “                     6.8 6.0 6.9
25th  “                     9.4 10.0 10.6 10.0
26th  “                    10.2 10.2 8.9 9.2
27th  “                    10.2 10.2 9.2 .2
28th  “                      5.0 8.9 8.9 6.2
29th  “                      6.0 7.9 8.5 8.2
30th  “                      4.9 6.8 7.0 6.7
31st  “                      6.2 7.8 7.3 6.7
32nd  “                     7.1 3.9 8.0 6.2
33rd  “                     6.9 9.7 6.9 11.3
34th  “                      7.5 7.0 8.8
35th  “                      8.3 9.2 7.8 7.8
36th  “                      8.3 8.7 8.1
37th  “                      6.6 7.9 11.8 9.0
38th  “                      6.0 6.1 5.6
39th  “                      7.4 7.7 10.0 9.7
40th  “                      7.6 7.0 6.4 
41st  “                      7.8 8.3 10.6
42nd  “ GH stopped 6.8 8.5 8.8
43rd  “                     7.0 6.7 8.6
44th  “                      6.2 8.5 5.6
45th  “                      6.2 7.1 6.2
Obs.: Normal glucose range 3.5 - 9.0 mmol/L;
Hypertonic glucose administered IV whenever glycemia < 4.5 mmol/L;
P.O. : Postoperative day;
Table 2: Blood glucose concentrations during the GH supplementation period
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RESUMO RHCFAP/2978
FAINTUCH, J. e col. - Baixos níveis
de glicemia e outras complicações
durante suplementação de hormô-
nio do crescimento na sepse.  Rev.
Hosp. Clin. Fac. Med. S. Paulo
54 (4): 135 - 138, 1999.
RESUMO:  O perfil glicêmico
esperado em pacientes pós-oper-
atórios sépticos recebendo nutrição
enteral de elevado teor calórico é de
valores sanguíneos no limite superior
do normal ou mesmo hiperglicemia
moderada.A adição de hormônio do
crescimento (GH) como agente
anabólico deveria reforçar ainda mais
esta tendência.Num paciente com
câncer submetido a gastrectomia par-
cial e linfadenectomia, que se compli-
cou no pós operatório com abscesso
subfrênico e sepse prolongada,
administrou-se conjuntamente dieta
de sonda (38,3 kcal/kg/dia) e GH (0,17
UI/kg/dia).Antes da introdução de GH
as taxas glicêmicas situavam-se nos
limites inferiores do normal, e esta
tendência persistiu durante a maior
parte do período terapêutico.Duas
complicações adicionais, nominal-
mente parada cardíaca e edema peri-
férico, foram documentadas nesta
mesma etapa.Conclui-se que a sepse é
o mais provável mecanismo de
redução da glicemia neste caso, e que
o emprego de dieta enteral e de GH
não conseguiu prevenir tal efeito.É
questionável se a parada cardíaca foi
devida ao suplemento hormonal, mas
o edema periférico é um secundarismo
bem conhecido deste agente em estu-
dos clínicos.
DESCRITORES: Hormônio do
crescimento. Nutrição enteral. Hi-
poglicemia. Sepse. Edema peri-
férico.
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